[go: up one dir, main page]

AR128816A2 - Formas de dosificación farmacéutica de perlas de cisteamina - Google Patents

Formas de dosificación farmacéutica de perlas de cisteamina

Info

Publication number
AR128816A2
AR128816A2 ARP230100660A ARP230100660A AR128816A2 AR 128816 A2 AR128816 A2 AR 128816A2 AR P230100660 A ARP230100660 A AR P230100660A AR P230100660 A ARP230100660 A AR P230100660A AR 128816 A2 AR128816 A2 AR 128816A2
Authority
AR
Argentina
Prior art keywords
pearls
sieve
retained
cysteamine
weight
Prior art date
Application number
ARP230100660A
Other languages
English (en)
Inventor
Kathlene Powell
Ramesh Muttavarapu
Ranjan Dohil
Original Assignee
Univ California
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR128816(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Horizon Orphan Llc filed Critical Univ California
Publication of AR128816A2 publication Critical patent/AR128816A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Fodder In General (AREA)

Abstract

Reivindicación 1: Una forma de dosificación farmacéutica, que comprende perlas de cisteamina de liberación retardada, caracterizada porque las perlas comprenden: (i) una partícula central que comprende cisteamina o una de sus sales farmacéuticamente aceptables y un aglutinante, y (ii) una membrana entérica que rodea la partícula central, en donde las perlas tienen una distribución de tamaños de partículas tal que: 0% de las perlas se retienen en un tamiz de 1700 mm; y luego menos del 5% en peso de las perlas se retienen en un tamiz de 1400 mm; y luego 20% a 30% en peso de las perlas se retienen en un tamiz de 1180 mm; y luego 50% a 70% en peso de las perlas se retienen en un tamiz de 1000 mm; y luego 10% a 20% en peso de las perlas se retienen en un tamiz de 850 mm.
ARP230100660A 2013-06-17 2023-03-16 Formas de dosificación farmacéutica de perlas de cisteamina AR128816A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17

Publications (1)

Publication Number Publication Date
AR128816A2 true AR128816A2 (es) 2024-06-19

Family

ID=52019418

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140102285A AR096628A1 (es) 2013-06-17 2014-06-16 Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
ARP230100660A AR128816A2 (es) 2013-06-17 2023-03-16 Formas de dosificación farmacéutica de perlas de cisteamina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140102285A AR096628A1 (es) 2013-06-17 2014-06-16 Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Country Status (25)

Country Link
US (9) US9233077B2 (es)
EP (2) EP3010491A4 (es)
JP (1) JP6468661B2 (es)
KR (2) KR102466253B1 (es)
CN (2) CN110664780B (es)
AP (1) AP2015008925A0 (es)
AR (2) AR096628A1 (es)
AU (1) AU2014281702C1 (es)
BR (1) BR112015031417B1 (es)
CA (2) CA2914770C (es)
CL (1) CL2015003662A1 (es)
CU (1) CU20150178A7 (es)
EA (1) EA031255B8 (es)
HK (1) HK1218066A1 (es)
IL (2) IL302141A (es)
MX (1) MX375377B (es)
NI (1) NI201500177A (es)
NZ (1) NZ714517A (es)
PH (2) PH12020552266A1 (es)
SG (1) SG11201510126QA (es)
TN (1) TN2015000549A1 (es)
TW (1) TWI649100B (es)
UA (1) UA117833C2 (es)
WO (1) WO2014204881A1 (es)
ZA (1) ZA201508783B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096629A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Métodos para analizar composiciones de cisteamina
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US10537528B2 (en) * 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
JP6908769B2 (ja) * 2017-03-15 2021-07-28 セレシン・インコーポレーテッド 高い薬物充填量の中鎖脂肪酸トリグリセリドを有する医薬組成物およびそれに関連する方法
JPWO2023249087A1 (es) * 2022-06-24 2023-12-28

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
US20030157191A1 (en) 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US6815434B2 (en) 2002-01-04 2004-11-09 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
KR101329369B1 (ko) 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CA2565250C (en) 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
KR20080002789A (ko) * 2005-03-29 2008-01-04 에보니크 룀 게엠베하 조절 물질의 전달에 영향을 미치는 매트릭스를 가지는펠렛을 포함하는 다중 미립자 제약 형태
US8822535B2 (en) 2005-04-20 2014-09-02 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
ES2774755T3 (es) 2006-01-27 2020-07-22 Univ California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
DK2214480T3 (da) 2007-11-30 2013-07-08 Univ California Fremgangsmåder til behandling af nonalkoholisk steatohepatitis (NASH) ved anvendelse af cysteaminprodukter
WO2009100950A1 (en) 2008-02-17 2009-08-20 Walcom Animal Science (I.P.3) Limited Materials and methods for improving the health of shrimp
EP2405898A2 (en) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
JP5619130B2 (ja) * 2009-03-18 2014-11-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ ＲｏｅｈｍＧｍｂＨ 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
JP6411215B2 (ja) * 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Also Published As

Publication number Publication date
EA201690036A1 (ru) 2016-09-30
IL302141A (en) 2023-06-01
ZA201508783B (en) 2019-09-25
US9173851B1 (en) 2015-11-03
US20160095827A1 (en) 2016-04-07
US20150290139A1 (en) 2015-10-15
NZ714517A (en) 2018-10-26
BR112015031417A8 (pt) 2021-06-22
TWI649100B (zh) 2019-02-01
HK1218066A1 (zh) 2017-02-03
PH12015502783A1 (en) 2016-03-21
IL284823A (en) 2021-08-31
CA2914770C (en) 2016-09-27
MX375377B (es) 2025-03-06
US20190298665A1 (en) 2019-10-03
EP3010491A4 (en) 2016-05-18
CA2938644A1 (en) 2014-12-24
CN110664780B (zh) 2022-09-27
US11090279B2 (en) 2021-08-17
AP2015008925A0 (en) 2015-12-31
BR112015031417B1 (pt) 2022-12-27
AU2014281702B2 (en) 2019-11-07
US20170319513A1 (en) 2017-11-09
BR112015031417A2 (pt) 2017-07-25
US20140370085A1 (en) 2014-12-18
KR20210094140A (ko) 2021-07-28
UA117833C2 (uk) 2018-10-10
CA2938644C (en) 2019-08-27
EP3939574A1 (en) 2022-01-19
WO2014204881A8 (en) 2016-02-18
KR20160045053A (ko) 2016-04-26
CN110664780A (zh) 2020-01-10
JP2016523250A (ja) 2016-08-08
CA2914770A1 (en) 2014-12-24
US9233077B2 (en) 2016-01-12
KR102466253B1 (ko) 2022-11-10
MX2015017366A (es) 2016-07-13
TW201534357A (zh) 2015-09-16
US20170319514A1 (en) 2017-11-09
PH12020552266A1 (en) 2022-04-25
NI201500177A (es) 2016-02-15
TN2015000549A1 (en) 2017-04-06
US20160158170A1 (en) 2016-06-09
CU20150178A7 (es) 2016-07-29
AU2014281702C1 (en) 2020-05-14
CN105492000A (zh) 2016-04-13
EA031255B8 (ru) 2019-11-29
AU2014281702A1 (en) 2015-12-10
WO2014204881A1 (en) 2014-12-24
EP3010491A1 (en) 2016-04-27
KR102281747B1 (ko) 2021-07-26
CL2015003662A1 (es) 2016-08-05
CN105492000B (zh) 2019-11-15
US20170319512A1 (en) 2017-11-09
EA031255B1 (ru) 2018-12-28
SG11201510126QA (en) 2016-01-28
JP6468661B2 (ja) 2019-02-13
AR096628A1 (es) 2016-01-20
US20160331704A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
AR128816A2 (es) Formas de dosificación farmacéutica de perlas de cisteamina
IL285972B (en) Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
DK3492455T3 (da) 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
BR112017022001A2 (pt) método para preparação da forma silico-aluminada da estrutura de zeólito aei com altos rendimentos e sua aplicação na catálise.
PT3116547T (pt) Nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para produzir e utilizar as mesmas
CU20170168A7 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
CU20160069A7 (es) Sistema multiparticulado para administrar drogas
HUE059630T2 (hu) Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik
HUE041983T2 (hu) Tofogliflozint tartalmazó szilárd készítmények és eljárás ezek elõállítására
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR110374A1 (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
SG11201502666XA (en) High dose extended-release potassium citrate wax matrix tablet